I branching formation in erythroid differentiation is regulated by transcription factor C/EBPα

Blood

Volumn 110, Issue 13, 2007, Pages 4526-4534

  Twu, Yuh Ching ^a   Chen, Chie Pein ^b   Hsieh, Chuang Yi ^a   Tzeng, Cheng Hwai ^c,d   Sun, Chien Feng ^e,f   Wang, Shih Hsin ^g   Chang, Mau Sun ^b   Yu, Lung Chih ^a,g  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP I ANTIGEN; CCAAT BINDING FACTOR; CD34 ANTIBODY; N ACETYLLACTOSAMINE SYNTHASE; TRANSCRIPTION FACTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; N ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLGLUCOSAMINYLTRANSFERASE IGNT; N-ACETYLGLUCOSAMINYLTRANSFERASE IGNT; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRUCTURE; CONTROLLED STUDY; ERYTHROID CELL; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; GENE LOCUS; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LENTIVIRINAE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; RETICULOCYTE; STEM CELL; ADULT; BLOOD GROUP I SYSTEM; CELL STRAIN K 562; CYTOLOGY; ERYTHROCYTE; FETUS BLOOD; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ADULT; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; ERYTHROCYTES; FETAL BLOOD; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMATOPOIETIC STEM CELLS; HUMANS; I BLOOD-GROUP SYSTEM; K562 CELLS; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHOSPHORYLATION;

EID: 39649083397     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-067801     Document Type: Article

References (52)

1. Niemann H, Watanabe K, Hakomori S, Childs RA, Feizi T. Blood group i and I activities of "lacto-N-norhexaosylceramide" and its analogues: the structural requirements for i-specificity. Biochem Biophys Res Commun. 1978;81:1286-1293.
2. Watanabe K, Hakomori S, Childs RA, Feizi T. Characterization of a blood group I-active ganglioside. J Biol Chem. 1979;254:3221-3228.
3. Koscielak J, Zdebska E, Wilczynska Z, Miller-Podraza H, Dzierzkowa-Borodej W. Immunochemistry of Ii-activity glycosphingolipids. Eur J Biochem. 1979;96:331-337.
4. Issitt PD, Anstee DJ. Applied Blood Group Serology. Durham, NC: Montgomery Scientific Publications; 1998.
5. Daniels G. Human Blood Groups. Oxford, England: Blackwell Science; 2002.
6. Wiener AS, Unger LJ, Cohen L, Feldman J. Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: biological test with bovine red cells. Ann Intern Med. 1956;44:221-240.
7. Jenkins WJ, Marsh WL, Noades J, Tippett P, Sanger R, Race RR. The I antigen and antibody. Vox Sang. 1960;5:97-106.
8. Tippett P, Noades J, Sanger R, et al. Further studies of the I antigen and antibody. Vox Sang. 1960;5:107-121.
9. Marsh WL, Jenkins WJ. Anti-i: a new cold antibody. Nature (London). 1960;188:753.
10. Marsh WL. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haematol. 1961;7:200-209.
11. Marsh WL, Nichols ME, Allen FH. Inhibition of anti-I sera by human milk. Vox Sang. 1970;18:149-154.
12. Rouger P, Juszczak G, Doinel C, Salmon C. Relationship between I and H antigens, I: a study of the plasma and saliva of a normal population. Transfusion. 1980;20:536-539.
13. Reid ME, Lomas-Francis C. The Blood Group Antigen FactsBook. San Diego, CA: Academic Press; 1997.
14. Fukuda M, Fukuda M, Hakomori S. Developmental change and genetic defect in the carbohydrate structure of band 3 glycoprotein of human erythrocyte membrane. J Biol Chem. 1979;254:3700-3703.
15. Piller F, Cartron J-P. Biosynthesis of blood group I antigens. J Biol Chem. 1984;259:13385-13390.
16. Marsh WL, Nichols ME, Reid ME. The definition of two I antigen components. Vox Sang. 1971;20:209-217.
17. Giblett ER, Crookston MC. Agglutinability of red cells by anti-i in patients with Thalassaemia major and other haematological disorders. Nature. 1964;201:1138-1139.
18. Romans DG, Tilley CA, Dorrington KJ. Monogamous bivalency of IgG antibodies, I: deficiency of branched ABHI-active oligosaccharide chains on red cells of infants causes the weak antiglobulin reactions in Hemolytic disease of the newborn due to ABO incompatibitity. J Immunol. 1980;124:2807-2811.
19. Hakomori S-I. Traveling for the glycosphingolipid path. Glycoconj J. 2000;17:627-647.
20. Bierhuizen MFA, Mattei M-G, Fukuda M. Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N- acetylglucosaminyltransferase gene family. Genes Dev. 1993;7:468-478.
21. Yu L-C, Twu Y-C, Chou M-L, et al. The molecular genetics of the human I locus and molecular background explain the partial association of the adult i phenotype with congenital cataracts. Blood. 2003;101:2081-2088.
22. Inaba N, Hiruma T, Togayachi A, et al. A novel I-branching β-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood. 2003;101:2870-2876.
23. Yu L-C, Twu Y-C, Chang C-Y, Lin M. Molecular basis of the adult i phenotype and the gene responsible for the expression of the human blood group I antigen. Blood. 2001;98:3840-3845.
24. Twu Y-C, Hsieh C-Y, Yu L-C. Expression of the histo-blood group B gene predominates in AB-genotype cells. Transfusion. 2006;46:1988-1996.
25. Ausubel FM, Brent R, Kingston, RE, et al. Current Protocols in Molecular Biology. Hoboken, NJ: John Wiley & Sons; 1998.
26. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukemia cell line K562. Nature. 1979;278:364-365.
27. Hoffman R, Murnane MJ, Benz EJ Jr, et al. Induction of erythropoietic colonies in a human chronic myelogenous leukemia cell line. Blood. 1979;54:1182-1187.
28. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS. Induction of γ-globin by histone deacetylase inhibitors. Blood. 1997;90:2075-2083.
29. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 2000;95:2391-2396.
30. Testa U, Henri A, Bettaieb A, et al. Regulation of iand I-antigen expression in the K562 cell line. Cancer Res. 1982;42:4694-4700.
31. Orkin SH, Harosi FI, Leder P. Differentiation in erythroleukemic cells and their somatic hybrids. Proc Nat Acad Sci U S A. 1975;72:98-102.
32. Schug J, Overton GC. TESS: Transcription Element Search Software on the WWW, Technical Report CBIL-TR-1997-1001-v0.0. Available at: http://www.cbil. upenn.edu/tess. Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylvania; 1997.
33. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365:561-575.
34. Mahoney CW, Shuman J, McKnight SL, Chen H-C, Huang K-P. Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding. J Biol Chem. 1992;267:19396-19403.
35. Ross SE, Radomska HS, Wu B, et al. Phosphorylation of C/EBPα inhibits granulopoiesis. Mol Cell Biol. 2004;24:675-686.
36. Wang G-L, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBPα growth inhibitory activity. Genes Dev. 2004;18:912-925.
37. Radomska HS, Basseres DS, Zheng R, et al. Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Environ Monit. 2006;203:371-381.
38. Subramanian L, Benson MD, Iniguez-Lluhi JA. A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein α inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J Biol Chem. 2003;278:9134-9141.
39. Lincoln AJ, Monczak Y, Williams SC, Johnson PF. Inhibition of CCAAT/enhancer-binding protein α and α translation by upstream open reading frames. J Biol Chem. 1998;273:9552-9560.
40. + cells. Blood. 2003;101:2206-2214.
41. Rosenfield RE. A-B hemolytic disease of the newborn: analysis of 1480 cord blood specimens, with special reference to the direct antiglobulin test and to the group O mother. Blood. 1955;10:17-28.
42. Klinman NR, Karush F. Equine anti-hapten antibody, V: the non-precipitability of bivalent antibody. Immunochemistry. 1967;4:387-405.
43. Hornick CL, Karush F. Antibody affinity, III: the role of multivalence. Immunochemistry. 1972;9:325-340.
44. Gopalakrishnan PV, Karush F. Antibody affinity, VII: multivalent interaction of anti-lactoside antibody. J Immunol. 1974;113:769-778.
45. Hakomori S, Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer I. 1983;71:231-251.
46. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci. 2005;118:2545-2555.
47. Tenen DG, Hromas R, Licht JD, Zhang D-E. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
48. Mueller BU, Pabst T. C/EBPα and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol. 2006;13:7-14.
49. Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity. 2004;21:853-863.
50. Zhang D-E, Zhang P, Wang N-D, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc Natl Acad Sci U S A. 1997;94:569-574.
51. An MR, Hsieh C-C, Reisner PD, et al. Evidence for posttranscriptional regulation of C/EBPα and C/EBPβ isoform expression during the lipopolysaccharide-mediated acute-phase response. Mol Cell Biol. 1996;16:2295-2306.
52. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30:48-58.